Teniposide and Cisplatin for Central Malignant Germ Cell Tumors

This study is focused on testing a combination of two drugs, Teniposide and Cisplatin, to treat newly diagnosed patients with central malignant germ cell tumors. These types of tumors occur in the brain or spinal cord and are particularly challenging to treat. The study aims to find out if this drug combination can effectively reduce or control the tumor, offering a new treatment option for patients facing this serious condition. Understanding how these drugs work together could lead to better treatment strategies for people with this rare and aggressive type of tumor. Participants in the study receive the treatment through an injection. Teniposide is given with Cisplatin every three weeks, and each cycle lasts between three to five days. The treatment involves a specific dosage of the drugs delivered through an intravenous drip, mixed with saline solution. Patients undergo up to six cycles of this combination therapy. After completing the chemotherapy cycles, standard radiation therapy is applied to further target tumor cells. The study does not list specific outcomes being measured, but the main goal is to evaluate the effectiveness and safety of this drug combination in managing the tumors.